{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:23:42Z","timestamp":1762867422087},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11906-018-0836-4","type":"journal-article","created":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T05:33:34Z","timestamp":1525152814000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The Complement Alternative Pathway and Preeclampsia"],"prefix":"10.1007","volume":"20","author":[{"given":"Layan","family":"Alrahmani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Alice V.","family":"Willrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,1]]},"reference":[{"key":"836_CR1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/01.AOG.0000437382.03963.88","volume":"122","author":"American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy","year":"2013","unstructured":"\u2022\u2022 American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Obstet Gynecol. 2013;122:1122\u201331. \n                      https:\/\/doi.org\/10.1097\/01.AOG.0000437382.03963.88\n                      \n                    . There are the guidelines for definitions and management of all forms of preeclampsia.","journal-title":"Obstet Gynecol"},{"key":"836_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.mam.2007.02.006","volume":"28","author":"S Saito","year":"2007","unstructured":"Saito S, Shiozaki A, Nakashima A, et al. The role of the immune system in preeclampsia. Mol Asp Med. 2007;28:192\u2013209. \n                      https:\/\/doi.org\/10.1016\/j.mam.2007.02.006\n                      \n                    .","journal-title":"Mol Asp Med"},{"key":"836_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1046\/j.1365-2249.1996.d01-809.x","volume":"106","author":"M Marzi","year":"1996","unstructured":"Marzi M, Vigano A, Trabattoni D, et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol. 1996;106:127\u201333.","journal-title":"Clin Exp Immunol"},{"key":"836_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/83183","volume":"2","author":"AL Mellor","year":"2001","unstructured":"Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D, et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol. 2001;2:64\u20138. \n                      https:\/\/doi.org\/10.1038\/83183\n                      \n                    .","journal-title":"Nat Immunol"},{"key":"836_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/aji.12481","volume":"75","author":"Y Ban","year":"2016","unstructured":"Ban Y, Zhao Y, Liu F, Dong B, Kong B, Qu X. Effect of indoleamine 2,3-dioxygenase expressed in HTR-8\/SVneo cells on decidual NK cell cytotoxicity. Am J Reprod Immunol. 2016;75:519\u201328. \n                      https:\/\/doi.org\/10.1111\/aji.12481\n                      \n                    .","journal-title":"Am J Reprod Immunol"},{"key":"836_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/14767050500072722","volume":"17","author":"K Richani","year":"2005","unstructured":"Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien JK, et al. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med. 2005;17:239\u201345. \n                      https:\/\/doi.org\/10.1080\/14767050500072722\n                      \n                    .","journal-title":"J Matern Fetal Neonatal Med"},{"key":"836_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785\u201397. \n                      https:\/\/doi.org\/10.1038\/ni.1923\n                      \n                    .","journal-title":"Nat Immunol"},{"key":"836_CR8","doi-asserted-by":"crossref","unstructured":"Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MAV (2016) Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation. pp 1\u201375.","DOI":"10.1016\/bs.acc.2016.06.001"},{"key":"836_CR9","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1016\/j.molimm.2009.04.029","volume":"46","author":"M Botto","year":"2009","unstructured":"Botto M, Kirschfink M, Macor P, Pickering MC, W\u00fcrzner R, Tedesco F. Complement in human diseases: lessons from complement deficiencies. Mol Immunol. 2009;46:2774\u201383. \n                      https:\/\/doi.org\/10.1016\/j.molimm.2009.04.029\n                      \n                    .","journal-title":"Mol Immunol"},{"key":"836_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/aji.12162","volume":"71","author":"MC Hoffman","year":"2014","unstructured":"\u2022\u2022 Hoffman MC, Rumer KK, Kramer A, Lynch AM, Winn VD. Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am J Reprod Immunol. 2014;71:55\u201360. \n                      https:\/\/doi.org\/10.1111\/aji.12162\n                      \n                    . Cross-section study in preeclampsia with severe features versus normal controls. Complement factor B activation fragment Bb (specific for complement alternative pathway) in bmaternal and umbilical venous blood appears to be increased in preeclamptics when compared to controls.","journal-title":"Am J Reprod Immunol"},{"key":"836_CR11","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Sones JL, Merriam AA, Seffens A, et al (2017) Angiogenic factor imbalance precedes complement deposition in placentae of the BPH\/5 model of preeclampsia. FASEB J fj.201701008R. doi: \n                      https:\/\/doi.org\/10.1096\/fj.201701008R\n                      \n                    . An animal study on gravid mice revealed complement gene up-regulation in high blood pressure mice compared to controls. Altered expression of VEGF pathway genes in high blood pressure mice implantation sites preceded complement dysregulation.","DOI":"10.1096\/fj.201701008R"},{"key":"836_CR12","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1067\/mob.2003.401","volume":"188","author":"JI Einarsson","year":"2003","unstructured":"Einarsson JI, Sangi-Haghpeykar H, Gardner MO. Sperm exposure and development of preeclampsia. Am J Obstet Gynecol. 2003;188:1241\u20133.","journal-title":"Am J Obstet Gynecol"},{"key":"836_CR13","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0140-6736(94)91638-1","volume":"344","author":"PY Robillard","year":"1994","unstructured":"Robillard PY, Hulsey TC, P\u00e9rianin J, et al. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet (London, England). 1994;344:973\u20135.","journal-title":"Lancet (London, England)"},{"key":"836_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0165-0378(99)00062-5","volume":"46","author":"CA Koelman","year":"2000","unstructured":"Koelman CA, Coumans AB, Nijman HW, et al. Correlation between oral sex and a low incidence of preeclampsia: a role for soluble HLA in seminal fluid? J Reprod Immunol. 2000;46:155\u201366.","journal-title":"J Reprod Immunol"},{"key":"836_CR15","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1097\/AOG.0000000000001340","volume":"127","author":"H-M Tsai","year":"2016","unstructured":"\u2022 Tsai H-M, Kuo E. From gestational hypertension and preeclampsia to atypical hemolytic uremic syndrome. Obstet Gynecol. 2016;127:907\u201310. \n                      https:\/\/doi.org\/10.1097\/AOG.0000000000001340\n                      \n                    . A case report in which a patient was misdiagnosed with preeclampsia and HELLP syndrome one pregnancy, TTP in another pregnancy, and was finally given the correct diagnosis for atypical HUS in her third pregnancy, demostrating the great imitators.","journal-title":"Obstet Gynecol"},{"key":"836_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0301-2115(02)00352-4","volume":"108","author":"KA Abraham","year":"2003","unstructured":"Abraham KA, Kennelly M, Dorman AM, Walshe JJ. Pathogenesis of acute renal failure associated with the HELLP syndrome: a case report and review of the literature. Eur J Obstet Gynecol Reprod Biol. 2003;108:99\u2013102.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"836_CR17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1681\/ASN.2004100861","volume":"16","author":"M Noris","year":"2005","unstructured":"Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:1035\u201350. \n                      https:\/\/doi.org\/10.1681\/ASN.2004100861\n                      \n                    .","journal-title":"J Am Soc Nephrol"},{"key":"836_CR18","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676\u201387. \n                      https:\/\/doi.org\/10.1056\/NEJMra0902814\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"836_CR19","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1097\/01.AOG.0000258281.22296.de","volume":"109","author":"BM Sibai","year":"2007","unstructured":"Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol. 2007;109:956\u201366. \n                      https:\/\/doi.org\/10.1097\/01.AOG.0000258281.22296.de\n                      \n                    .","journal-title":"Obstet Gynecol"},{"key":"836_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.transci.2016.04.009","volume":"54","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F. Pregnancy-related thrombotic microangiopathies: clues from complement biology. Transfus Apher Sci. 2016;54:199\u2013202. \n                      https:\/\/doi.org\/10.1016\/j.transci.2016.04.009\n                      \n                    .","journal-title":"Transfus Apher Sci"},{"key":"836_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.thromres.2016.03.014","volume":"142","author":"L Sabau","year":"2016","unstructured":"\u2022\u2022 Sabau L, Terriou L, Provot F, Fourrier F, Roumier C, Caron C, et al. Are there any additional mechanisms for haemolysis in HELLP syndrome? Thromb Res. 2016;142:40\u20133. \n                      https:\/\/doi.org\/10.1016\/j.thomres.2016.03.014\n                      \n                    . Prospective observational study of 16 HELLP patients demonstrated that complement dysregulation is a prominent mechanism in hemolysis in these patients.","journal-title":"Thromb Res"},{"key":"836_CR22","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/HYPERTENSIONAHA.113.01420","volume":"62","author":"RM Burwick","year":"2013","unstructured":"\u2022 Burwick RM, Fichorova RN, Dawood HY, Yamamoto HS, Feinberg BB. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension. 2013;62:1040\u20135. \n                      https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.01420\n                      \n                    . Case\u2013control study in which those with preeclampsia had marked elevations in urinary C5b-9. Although complement elevations of complement components were noted, they did not differ preeclampsia from chronic hypertension, supporting the hypothesis that complement markers in urine, rather than plasma, better reflect complement dysregulation.","journal-title":"Hypertension"},{"key":"836_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/AOG.0b013e3181fc3afa","volume":"117","author":"AM Lynch","year":"2011","unstructured":"Lynch AM, Gibbs RS, Murphy JR, Giclas PC, Salmon JE, Holers VM. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol. 2011;117:75\u201383. \n                      https:\/\/doi.org\/10.1097\/AOG.0b013e3181fc3afa\n                      \n                    .","journal-title":"Obstet Gynecol"},{"key":"836_CR24","doi-asserted-by":"publisher","first-page":"385.e1","DOI":"10.1016\/j.ajog.2007.10.793","volume":"198","author":"AM Lynch","year":"2008","unstructured":"Lynch AM, Murphy JR, Byers T, Gibbs RS, Neville MC, Giclas PC, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol. 2008;198:385.e1\u20139. \n                      https:\/\/doi.org\/10.1016\/j.ajog.2007.10.793\n                      \n                    .","journal-title":"Am J Obstet Gynecol"},{"key":"836_CR25","doi-asserted-by":"publisher","unstructured":"\u2022 Ma Y, Kong L-R, Ge Q, et al. Complement 5a-mediated trophoblasts dysfunction is involved in the development of pre-eclampsia. J Cell Mol Med. 2017; \n                      https:\/\/doi.org\/10.1111\/jcmm.13466\n                      \n                    . This study demonstrates that complement 5a (C5a) plays a pivotal role in aberrant placentation by detecting elevated C5a deposition in macrophages and C5a receptor expression in trophoblasts of preeclamptic placentas.","DOI":"10.1111\/jcmm.13466"},{"key":"836_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acc.2016.06.001","volume":"77","author":"A Frazer-Abel","year":"2016","unstructured":"\u2022\u2022 Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MAV. Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation. Adv Clin Chem. 2016;77:1\u201375. \n                      https:\/\/doi.org\/10.1016\/bs.acc.2016.06.001\n                      \n                    . The basis of complement testing in common diseases affected by complement dysregulation is described in depth in this article.","journal-title":"Adv Clin Chem"},{"key":"836_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"\u2022 Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15\u201339. \n                      https:\/\/doi.org\/10.1007\/s00467-015-3076-8\n                      \n                    . An international consensus to approaching the diagnosis and management of atypical HUS in children. Here, HELLP syndrome is classified as as TMA.","journal-title":"Pediatr Nephrol"},{"key":"836_CR28","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.mayocp.2016.05.015","volume":"91","author":"RS Go","year":"2016","unstructured":"\u2022 Go RS, Winters JL, Leung N, Murray DL, Willrich MA, Abraham RS, et al. Thrombotic microangiopathy care pathway: a consensus statement for the Mayo Clinic complement alternative pathway-thrombotic microangiopathy (CAP-TMA) disease-oriented group. Mayo Clin Proc. 2016;91:1189\u2013211. \n                      https:\/\/doi.org\/10.1016\/j.mayocp.2016.05.015\n                      \n                    . The Mayo Clinic approach to diagnosis of complement alternative pathway thrombotic microangiopathy disorders is described here, which includes atypical HUS.","journal-title":"Mayo Clin Proc"},{"key":"836_CR29","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1182\/blood-2008-03-144691","volume":"112","author":"F Fakhouri","year":"2008","unstructured":"\u2022 Fakhouri F, Jablonski M, Lepercq J, Blouin J, Benachi A, Hourmant M, et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood. 2008;112:4542\u20135. \n                      https:\/\/doi.org\/10.1182\/blood-2008-03-144691\n                      \n                    . An early report of genetic variants in complement alternative pathway regulatory proteins in 11 patients with HELLP syndrome.","journal-title":"Blood"},{"key":"836_CR30","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3109\/14767058.2012.694923","volume":"25","author":"F Crovetto","year":"2012","unstructured":"Crovetto F, Borsa N, Acaia B, Nishimura C, Frees K, Smith RJH, et al. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J Matern Fetal Neonatal Med. 2012;25:2322\u20135. \n                      https:\/\/doi.org\/10.3109\/14767058.2012.694923\n                      \n                    .","journal-title":"J Matern Fetal Neonatal Med"},{"key":"836_CR31","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","volume":"111","author":"M J\u00f3zsi","year":"2008","unstructured":"J\u00f3zsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency. Blood. 2008;111:1512\u20134. \n                      https:\/\/doi.org\/10.1182\/blood-2007-09-109876\n                      \n                    .","journal-title":"Blood"},{"key":"836_CR32","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2010030315","volume":"21","author":"M-A Dragon-Durey","year":"2010","unstructured":"Dragon-Durey M-A, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010;21:2180\u20137. \n                      https:\/\/doi.org\/10.1681\/ASN.2010030315\n                      \n                    .","journal-title":"J Am Soc Nephrol"},{"key":"836_CR33","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1681\/ASN.2006080811","volume":"18","author":"A-L Sellier-Leclerc","year":"2007","unstructured":"Sellier-Leclerc A-L, Fremeaux-Bacchi V, Dragon-Durey M-A, Macher MA, Niaudet P, Guest G, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18:2392\u2013400. \n                      https:\/\/doi.org\/10.1681\/ASN.2006080811\n                      \n                    .","journal-title":"J Am Soc Nephrol"},{"key":"836_CR34","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.exphem.2016.01.005","volume":"44","author":"AJ Vaught","year":"2016","unstructured":"\u2022\u2022 Vaught AJ, Gavriilaki E, Hueppchen N, Blakemore K, Yuan X, Seifert SM, et al. Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome. Exp Hematol. 2016;44:390\u20138. \n                      https:\/\/doi.org\/10.1016\/j.exphem.2016.01.005\n                      \n                    . A comprehensive study demonstrating alternative complement pathway activation in preeclamptics and those with HELLP syndrome, in addition to demonstrating a significant decrease in cell killing after mizing HELLP serum with eculizumab-containing serum.","journal-title":"Exp Hematol"},{"key":"836_CR35","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/AOG.0b013e31828e2612","volume":"122","author":"G Ardissino","year":"2013","unstructured":"Ardissino G, Wally Ossola M, Baffero GM, et al. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol. 2013;122:487\u20139. \n                      https:\/\/doi.org\/10.1097\/AOG.0b013e31828e2612\n                      \n                    .","journal-title":"Obstet Gynecol"},{"key":"836_CR36","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","volume":"373","author":"RJ Kelly","year":"2015","unstructured":"Kelly RJ, H\u00f6chsmann B, Szer J, Kulasekararaj A, de Guibert S, R\u00f6th A, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373:1032\u20139. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1502950\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"836_CR37","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08099.x","volume":"149","author":"R Kelly","year":"2010","unstructured":"Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol. 2010;149:446\u201350. \n                      https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08099.x\n                      \n                    .","journal-title":"Br J Haematol"},{"key":"836_CR38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.imbio.2014.11.003","volume":"220","author":"RF Hallstensen","year":"2015","unstructured":"Hallstensen RF, Bergseth G, Foss S, J\u00e6ger S, Gedde-Dahl T, Holt J, et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology. 2015;220:452\u20139. \n                      https:\/\/doi.org\/10.1016\/j.imbio.2014.11.003\n                      \n                    .","journal-title":"Immunobiology"},{"key":"836_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","volume":"34","author":"RM Burwick","year":"2013","unstructured":"\u2022\u2022 Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia\/HELLP syndrome. Placenta. 2013;34:201\u20133. \n                      https:\/\/doi.org\/10.1016\/j.placenta.2012.11.014\n                      \n                    . A report of one case of HELLP syndrome at 26\u00a0weeks in which the patient was started on eculizumab and the pregnancy was safely prolonged by approximately 3\u00a0weeks.","journal-title":"Placenta"},{"key":"836_CR40","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"\u2022 McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66:734\u20137. \n                      https:\/\/doi.org\/10.15585\/mmwr.mm6627e1\n                      \n                    . A report by the Center for Disease Control and Prevention demonstrating 16 cases of meningococcal disease in those receiving eculizumab between 2008\u20132016, despite receipt of the vaccine.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"836_CR41","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/ki.2013.373","volume":"85","author":"A Sinha","year":"2014","unstructured":"Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 2014;85:1151\u201360. \n                      https:\/\/doi.org\/10.1038\/ki.2013.373\n                      \n                    .","journal-title":"Kidney Int"},{"key":"836_CR42","doi-asserted-by":"publisher","unstructured":"Heggermont WA, Verhelst C, De Wilde K, et al. A case of HELLP syndrome: an immuno-\u201clogical\u201d approach. Acta Clin Belg. 67:375\u20137. \n                      https:\/\/doi.org\/10.2143\/ACB.67.5.2062695\n                      \n                    .","DOI":"10.2143\/ACB.67.5.2062695"},{"key":"836_CR43","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.tjog.2012.07.018","volume":"51","author":"M-M Chou","year":"2012","unstructured":"Chou M-M, Chen Y-F, Kung H-F, Liu CK, Sun L, Chen WC, et al. Extensive hepatic infarction in severe preeclampsia as part of the HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): evolution of CT findings and successful treatment with plasma exchange therapy. Taiwan J Obstet Gynecol. 2012;51:418\u201320. \n                      https:\/\/doi.org\/10.1016\/j.tjog.2012.07.018\n                      \n                    .","journal-title":"Taiwan J Obstet Gynecol"},{"key":"836_CR44","first-page":"243","volume":"5","author":"J Vafaeimanesh","year":"2014","unstructured":"Vafaeimanesh J, Nazari A, Hosseinzadeh F. Plasmapheresis: lifesaving treatment in severe cases of HELLP syndrome. Casp J Intern Med. 2014;5:243\u20137.","journal-title":"Casp J Intern Med"},{"key":"836_CR45","doi-asserted-by":"publisher","first-page":"e1764","DOI":"10.1542\/peds.2013-1594","volume":"133","author":"B Diamante Chiodini","year":"2014","unstructured":"Diamante Chiodini B, Davin J-C, Corazza F, Khaldi K, Dahan K, Ismaili K, et al. Eculizumab in anti-factor H antibodies associated with atypical hemolytic uremic syndrome. Pediatrics. 2014;133:e1764\u20138. \n                      https:\/\/doi.org\/10.1542\/peds.2013-1594\n                      \n                    .","journal-title":"Pediatrics"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-018-0836-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-018-0836-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-018-0836-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:14:15Z","timestamp":1556669655000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-018-0836-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1007\/s11906-018-0836-4","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"1 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflicts of interest relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"40"}}